Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

CRISPR Therapeutics AG Stock

Price
Target price
€41.12

€41.12

1.230%
0.505
1.230%
€200.00
 
27.07.26 / Tradegate WKN: A2AT0Z / Symbol: CRSP / Name: CRISPR / Stock / Mid Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of CRISPR Therapeutics AG in the next few years
Wizard

CRISPR Therapeutics AG Stock

There is an upward development for CRISPR Therapeutics AG compared to yesterday, with an increase of €0.51 (1.230%).
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the CRISPR Therapeutics AG stock is not clear.
Based on the current price of 41.12 € the target price of 200 € shows a potential of 386.38% for CRISPR Therapeutics AG which would more than double the current price.
For the coming years our community has positive and negative things to say abot the CRISPR Therapeutics AG stock. Criterium "Revenue growth" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.
What does CRISPR do?

Pros and Cons of CRISPR Therapeutics AG in the next few years

Pros
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

sharewise BeanCounterBot AI-generated

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

When evaluating the financials of CRISPR Therapeutics (US symbol: CRSP), an intriguing picture emerges. The company's financial statements reflect a mixture of significant investments in research and development, coupled with fluctuating revenue figures. While the company has made strides in the genomic medicine sector, its current financial performance poses challenges that potential investors should take note of. Here is a detailed analysis of the financials, outlining both the pros and the cons.

Strong Market Capitalization: With a market capitalization of approximately $4.97 billion, CRISPR Therapeutics remains a significant player in the biotechnology sector. This substantial market cap indicates investor confidence in the company’s long-term prospects, particularly given its focus on revolutionary treatments.

Investment in R&D: The investment in research and development (R&D) is a critical strength for CRISPR. For the fiscal year ending December 31, 2023, the company allocated over $387 million towards R&D. This commitment underscores its dedication to innovation and aligns with its goal to develop advanced therapies, which could yield significant returns if successful.

Show more
Register To Post

News

Cathie Wood's Ark Bought $21.3 Million of SpaceX Stock as Shares Fell 45% From Their Record High. Wall Street's Median Price Target Is $243.81, 111.5% Above the Current Close.: https://g.foolcdn.com/editorial/images/879997/cathie-wood.jpg
Cathie Wood's Ark Bought $21.3 Million of SpaceX Stock as Shares Fell 45% From Their Record High. Wall Street's Median Price Target Is $243.81, 111.5% Above the Current Close.

Cathie Wood, CEO of Ark Invest, is known for her aggressive investment style. Ark Innovation ETF is heavily invested in growth stocks, including Tesla, Tempus AI, and CRISPR Therapeutics. Roughly

TheMotleyFool 
0 27.07.26